JP2022532116A5 - - Google Patents

Info

Publication number
JP2022532116A5
JP2022532116A5 JP2021566141A JP2021566141A JP2022532116A5 JP 2022532116 A5 JP2022532116 A5 JP 2022532116A5 JP 2021566141 A JP2021566141 A JP 2021566141A JP 2021566141 A JP2021566141 A JP 2021566141A JP 2022532116 A5 JP2022532116 A5 JP 2022532116A5
Authority
JP
Japan
Prior art keywords
invention described
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021566141A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022532116A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2020/050613 external-priority patent/WO2020223811A1/en
Publication of JP2022532116A publication Critical patent/JP2022532116A/ja
Publication of JP2022532116A5 publication Critical patent/JP2022532116A5/ja
Pending legal-status Critical Current

Links

JP2021566141A 2019-05-06 2020-05-06 抗生物質カンナビノイド-テルペン製剤 Pending JP2022532116A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962843687P 2019-05-06 2019-05-06
US62/843,687 2019-05-06
PCT/CA2020/050613 WO2020223811A1 (en) 2019-05-06 2020-05-06 Antibiotic cannabinoid-terpene formulations

Publications (2)

Publication Number Publication Date
JP2022532116A JP2022532116A (ja) 2022-07-13
JP2022532116A5 true JP2022532116A5 (enExample) 2023-05-11

Family

ID=73050953

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021566141A Pending JP2022532116A (ja) 2019-05-06 2020-05-06 抗生物質カンナビノイド-テルペン製剤

Country Status (11)

Country Link
US (3) US20220218654A1 (enExample)
EP (1) EP3965794A4 (enExample)
JP (1) JP2022532116A (enExample)
KR (1) KR20220005066A (enExample)
CN (1) CN113710263A (enExample)
AU (1) AU2020270175A1 (enExample)
CA (1) CA3138811A1 (enExample)
IL (1) IL287729A (enExample)
MX (1) MX2021013656A (enExample)
SG (1) SG11202110779SA (enExample)
WO (1) WO2020223811A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021013656A (es) * 2019-05-06 2022-01-06 Univ British Columbia Formulaciones antibioticas de cannabinoides-terpenos.
KR102524364B1 (ko) * 2022-10-24 2023-04-24 전북대학교산학협력단 칸나비디올 및 타우린을 포함하는 치주염 예방 또는 치료용 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630507B1 (en) 1998-04-21 2003-10-07 The United States Of America As Represented By The Department Of Health And Human Services Cannabinoids as antioxidants and neuroprotectants
US7323576B2 (en) 2004-10-01 2008-01-29 Alphora Research Inc. Synthetic route to dronabinol
WO2012012498A2 (en) 2010-07-20 2012-01-26 Pulmatrix, Inc. Use of trp channel agonists to treat infections
CN107405314A (zh) * 2015-02-27 2017-11-28 埃布公司 包含纯化的大麻素与至少一种类黄酮、萜或矿物质的组合的组合物
AU2016225026A1 (en) * 2015-02-27 2017-09-07 Canopy Growth Corporation Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral
EP3380096A4 (en) * 2015-11-24 2019-10-23 Constance Therapeutics, Inc. CANNABIS OIL COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
WO2018011813A1 (en) 2016-07-14 2018-01-18 Therapix Biosciences Ltd. Compositions and methods of potentiating antimicrobials
CA3067542A1 (en) * 2017-06-19 2018-12-27 Syddansk Universitet Bacitracin and/or daptomycin combined with cannabidiol for treatment of bacterial infections
WO2019198056A1 (en) * 2018-04-14 2019-10-17 Buzzelet Development And Technologies Ltd Terpene-enriched cannabinoid composition for treating conditions and/ or symptoms associated with a stressful event
WO2020000024A1 (en) * 2018-06-28 2020-01-02 Botanix Pharmaceuticals Ltd Antibacterial treatment using cannabinoid combinations
CA3111979A1 (en) * 2018-09-05 2020-03-12 Nemus Bioscience, Inc. Cannabinoids for the treatment of gram-positive infections including antibiotic-resistant bacterial strains
MX2021013656A (es) * 2019-05-06 2022-01-06 Univ British Columbia Formulaciones antibioticas de cannabinoides-terpenos.

Similar Documents

Publication Publication Date Title
JP2022028828A5 (enExample)
JP2022025124A5 (enExample)
JP2021169491A5 (enExample)
JP2021185136A5 (enExample)
JP2022068302A5 (enExample)
JP2021028398A5 (enExample)
JP2024023385A5 (enExample)
JP2023116721A5 (enExample)
JP2021038271A5 (enExample)
JP2023022224A5 (enExample)
JP2020127428A5 (enExample)
JP2022523200A5 (enExample)
JP2020042034A5 (enExample)
JP2024016014A5 (enExample)
JP2021518389A5 (enExample)
JP2023100643A5 (enExample)
JP2022060295A5 (enExample)
JP2025506484A5 (enExample)
JP2022537813A5 (enExample)
JP2020171301A5 (enExample)
JP2020120660A5 (enExample)
JP2021524864A5 (enExample)
JP2022022379A5 (enExample)
JP2023085551A5 (enExample)
JP2020141705A5 (enExample)